Adalimumab treatment for SAPHO syndrome

Acta Dermato-Venereologica

Volumn 90, Issue 3, 2010, Pages 301-302

  Arias Santiago, Salvador ^a   Sanchez Cano, Daniel ^a   Callejas Rubio, José Luis ^a   Fernández Pugnaire, María Antonia ^a   Ortego Centeno, Norberto ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CLOBETASOL; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RISEDRONIC ACID;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LABORATORY TEST; LETTER; PRIORITY JOURNAL; SAPHO SYNDROME; THORAX RADIOGRAPHY;

ACQUIRED HYPEROSTOSIS SYNDROME; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MIDDLE AGED; STEROIDS; TREATMENT OUTCOME;

EID: 77953403502     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0822     Document Type: Letter

References (11)

1. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Le syndrome pustulose hyperostose osteite (SAPHO). Resultats d'une enquête nationale: 85 observations. Rev Rhum Mal Osteoartic 1987; 54: 187-196.
2. Wagner AD, Andresen J, Jendro MC, Hülsemann JL, Zeidler H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002; 46: 1965-1968.
3. Benhamou CL, Chamot AM, Kahn MF. Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO): a new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 1988; 6: 109-112.
4. Moll C, Hernández MV, Cañete JD, Gómez-Puerta JA, Soriano A, Collado, et al. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum 2008; 37: 299-306.
5. Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 2006; 45: 730-733.
6. Kahn MF, Khan MA. The SAPHO syndrome. Baillieres Clin Rheumatol 1994; 8: 333-362.
7. Belostocki K, Pricop L, Redecha PB, Aydin A, Leff L, Harrison MJ, et al. Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 384-388.
8. Matsumoto T, Kaneko T, Seto M, Wada H, Kobayashi T, Nakatani K, et al. The membrane proteinase 3 expression on neutrophils was downregulated after treatment with infliximab in patients with rheumatoid arthritis. Clin Appl Thromb Hemost 2008; 14: 186-192.
9. Pay S, Musaback U, Erdem H, Simsek I, Pekel A, Sengul A, et al. Chimerical anti-TNF-alpha, infliximab, inhibits neutrophil chemotaxis and production of reactive oxygen species by blocking the priming effect of mononuclear cells on neutrophils. Immunopharmacol Immunotoxicol 2005; 27: 187-198.
10. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-491.
11. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1-14.